Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 5:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 6,987 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Carcinoma Clear all
Recruiting No phase listed Observational

Oncoplastic Surgery Outcomes Database

NCT07597837
View directory record Official record
Conditions
Breast Cancer
Interventions
Oncoplastic Breast Surgery
Procedure
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2045
U.S. locations
2
States / cities
Boston, Massachusetts • Melrose, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 14, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate

NCT02581839
View directory record Official record
Conditions
Metastatic Breast Cancer, Brain Metastases
Interventions
Eribulin Mesylate, MRI, Pre-Medication: Zofran, Pre-Medication: Decadron
Drug · Device
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Oct 14, 2026, 5:14 PM EDT
Active, not recruiting Phase 1 Interventional Results available

Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery

NCT03317405
View directory record Official record
Conditions
Breast Carcinoma In Situ, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Interventions
Endoxifen Hydrochloride, Placebo Administration, Questionnaire Administration
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
3
States / cities
Los Angeles, California • Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 14, 2026, 5:14 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Sunitinib, Cyclophosphamide, and Methotrexate in Treating Patients With Metastatic Breast Cancer

NCT00616122
View directory record Official record
Conditions
Breast Cancer
Interventions
cyclophosphamide, methotrexate, sunitinib malate, laboratory biomarker analysis
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 120 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 14, 2026, 5:14 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Earlier Breast Cancer Detection Using Automated Whole Breast Ultrasound With Mammography, Including Cost Comparisons

NCT00649337
View directory record Official record
Conditions
Breast Neoplasms, Ultrasonography
Interventions
Comparison of Automated Whole Breast Ultrasound Screening with Blinded Screening Mammography
Procedure
Lead sponsor
SonoCine, Inc.
Industry
Eligibility
35 Years to 90 Years · Female only
Enrollment
4,650 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2010
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2008 · Synced Oct 14, 2026, 5:14 PM EDT
Completed Phase 1 Interventional

Multipeptide Vaccine for Advanced Breast Cancer

NCT00573495
View directory record Official record
Conditions
Breast Neoplasm, Breast Cancer, Cancer of the Breast, Carcinoma, Ductal
Interventions
hTERT/Survivin Multi-Peptide Vaccine
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced Oct 14, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting

NCT00618657
View directory record Official record
Conditions
Breast Cancer, HER2-negative Breast Cancer, HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
Carboplatin, paclitaxel albumin-stabilized nanoparticle formulation, bevacizumab, trastuzumab, magnetic resonance imaging, therapeutic conventional surgery
Drug · Procedure
Lead sponsor
University of California, Irvine
Other
Eligibility
21 Years to 90 Years · Female only
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2021
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 14, 2026, 5:14 PM EDT
Completed Not applicable Interventional Results available

Adaptive Training Exercise Programs for Improving Cardiorespiratory Fitness After Breast Cancer Treatment, The ACTIVATE Trial

NCT04667481
View directory record Official record
Conditions
Breast Cancer, Invasive Breast Carcinoma
Interventions
Aerobic Exercise Intervention, Resistance Exercise Intervention, Exercise Intervention: Digital copies and outline of sessions, Questionnaire Administration, Quality-of-Life Assessment
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 12, 2024 · Synced Oct 14, 2026, 5:14 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive

NCT02153905
View directory record Official record
Conditions
Breast Cancer, Cervical Cancer, Renal Cancer, Melanoma, Bladder Cancer
Interventions
Aldesleukin, Fludarabine, Cyclophosphamide, Anti-MAGE-A3 human leukocyte antigen serotype within HLA-A A serotype group (HLA-A* 01)-restricted T-cell receptor (TCR)
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 17, 2019 · Synced Oct 14, 2026, 5:14 PM EDT
Not listed Phase 1 Interventional

A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors

NCT04460456
View directory record Official record
Conditions
HER2 Positive Solid Tumors
Interventions
SBT6050, pembrolizumab, Cemiplimab
Drug
Lead sponsor
Silverback Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
Boston, Massachusetts • Durham, North Carolina • Pittsburgh, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Oct 14, 2026, 5:14 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Making Informed Choices on Incorporating Chemoprevention Into Care (MiCHOICE)

NCT04496739
View directory record Official record
Conditions
Atypical Hyperplasia of the Breast, Lobular Breast Carcinoma In Situ, Pleomorphic Lobular Breast Carcinoma In Situ
Interventions
Cancer Educational Materials, Decision Aid, Interview, Questionnaire Administration
Behavioral · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
412 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2028
U.S. locations
96
States / cities
Antioch, California • Costa Mesa, California • Duarte, California + 67 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 14, 2026, 5:14 PM EDT
Active, not recruiting Phase 2 Interventional

Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord

NCT02713269
View directory record Official record
Conditions
Malignant Digestive System Neoplasm, Metastatic Head and Neck Carcinoma, Metastatic Kidney Carcinoma, Metastatic Malignant Neoplasm in the Spine, Metastatic Malignant Neoplasm of Unknown Primary, Metastatic Melanoma, Prostate Carcinoma Metastatic in the Bone, Sarcoma, Solid Neoplasm, Spinal Cord Compression, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Lung Non-Small Cell Cancer AJCC v7, Thyroid Gland Carcinoma
Interventions
Computed Tomography, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery, Thermal Ablation Therapy
Procedure · Other · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 14, 2026, 5:14 PM EDT
Recruiting Phase 3 Interventional

A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

NCT07647328
View directory record Official record
Conditions
ER-Positive HER2-Negative Breast Cancer
Interventions
Camizestrant, Ribociclib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
12
States / cities
Duarte, California • Palo Alto, California • Marietta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 14, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases

NCT02595905
View directory record Official record
Conditions
Metastatic BRCA Hereditary Breast Carcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Triple-Negative Breast Carcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Cisplatin, Laboratory Biomarker Analysis, Placebo Administration, Veliparib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
798
States / cities
Anchorage, Alaska • Fort Smith, Arkansas • Hot Springs, Arkansas + 542 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 14, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer

NCT00499122
View directory record Official record
Conditions
Breast Cancer
Interventions
Cyclophosphamide, Docetaxel, Doxorubicin, NOV 002
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Miami, Florida • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 2, 2018 · Synced Oct 14, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Mindfulness-Based Intervention in Breast Cancer Patients Undergoing Chemotherapy

NCT02067351
View directory record Official record
Conditions
Breast Cancer
Interventions
Mindfulness
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
20 Years to 75 Years · Female only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Oct 14, 2026, 5:14 PM EDT
Completed Phase 1 Interventional

Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors

NCT00054977
View directory record Official record
Conditions
Colorectal Cancer, Lung Cancer, Breast Cancer, Head and Neck Cancer, Prostate Cancer
Interventions
GM-CT-01, 5-fluorouracil
Drug
Lead sponsor
Galectin Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
4
States / cities
Jacksonville, Florida • New Orleans, Louisiana • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2012 · Synced Oct 14, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients

NCT00270894
View directory record Official record
Conditions
Breast Neoplasm
Interventions
epirubicin, cyclophosphamide, docetaxel, trastuzumab
Drug
Lead sponsor
Accelerated Community Oncology Research Network
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
7
States / cities
Miami, Florida • Augusta, Georgia • Macon, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2012 · Synced Oct 14, 2026, 5:14 PM EDT
Completed No phase listed Observational

Effects of Chemotherapy on Intestinal Bacteria in Patients With Newly Diagnosed Breast Cancer

NCT02370277
View directory record Official record
Conditions
Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma, Stage I Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer
Interventions
Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis, Questionnaire Administration
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Oct 14, 2026, 5:14 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Predictors of Adjuvant Endocrine Therapy in Women With Breast Cancer

NCT02992730
View directory record Official record
Conditions
Breast Cancer Female
Interventions
No Intervention
Behavioral
Lead sponsor
Georgetown University
Other
Eligibility
21 Years and older · Female only
Enrollment
630 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2019
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 7, 2019 · Synced Oct 14, 2026, 5:14 PM EDT
Completed Phase 1 Interventional

Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer

NCT03012230
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Bone, Stage IV Breast Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma
Interventions
Laboratory Biomarker Analysis, Pembrolizumab, Ruxolitinib Phosphate
Other · Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Oct 14, 2026, 5:14 PM EDT
Recruiting Early Phase 1 Interventional

Feasibility Evaluation of the Muse Magnetic Resonance Guided Focused Ultrasound System

NCT05291507
View directory record Official record
Conditions
Breast Cancer
Interventions
Muse MRgFUS System
Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 14, 2026, 5:14 PM EDT
Completed Not applicable Interventional

Scalable Communication Modalities for Returning Genetic Research Results

NCT04407611
View directory record Official record
Conditions
Hereditary Breast and Ovarian Cancer, Lynch Syndrome
Interventions
Online modality, Genetic counselor follow-up
Behavioral
Lead sponsor
Boston University
Other
Eligibility
40 Years and older · Female only
Enrollment
926 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 14, 2026, 5:14 PM EDT
Not yet recruiting Phase 2 Interventional

Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast Cancer

NCT07619365
View directory record Official record
Conditions
Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
Interventions
Trastuzumab deruxtecan, Lovastatin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 14, 2026, 5:14 PM EDT